The American Gastroenterological Association (AGA) has announced that their latest guideline, “The AGA Living Guideline: Pharmacological Management of Moderate-To-Severe Ulcerative Colitis,” is now open for public comment. This guideline, aimed at supporting practitioners in the pharmacological management of moderate-to-severe ulcerative colitis (UC), features 14 recommendations designed to guide therapy decisions with a patient-centered approach.

Referred to as a “living guideline,” this document serves as an update to AGA’s 2020 guideline, located here. The updated guideline incorporates new evidence to ensure the most up-to-date recommendations. The finalized version of this guideline is expected to be published in December 2024.

As part of AGA’s development process, they invite reviews and feedback from the public. Interested parties are encouraged to submit their comments here by July 31, 2024. Your input is valuable in shaping the future of UC management.

Copyright © 2024 Guideline Central, all rights reserved.